The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis

Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings. 

Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities. 

Key Market Insights

More than 175 service providers claim to offer services for biologic fill / finish operations

The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide.

Several partnerships have been established in the biologics fill / finish services domain, since 2013

Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines.

Over 170 expansions have been reported in biologics fill / finish services domain, since 2013

More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations.     

The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters

 Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees).

The demand for biologics fill / finish services is expected to grow at an annualized rate of 14%

Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region.

Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035

In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/256/request-sample.html

Key Questions Answered

• What is fill / finish?
• Who are the key players offering biologics fill / finish services?
• Where are biologics fill / finish facilities located?
• What is the market share of ampoules, cartridges, vials, and syringes in fill / finish?
• What types of expansion initiatives are being undertaken by players in this domain?
• What is the current demand for biologics fill / finish services?
• What is the current and future market size for biologics fill / finish services?

The financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:

• Type of Packaging Container
• Ampoules
• Cartridges
• Syringes
• Vials

• Type of Biologic
• Antibodies
• Cell Therapies
• Gene Therapies
• Oligonucleotides
• Proteins / Peptides
• Vaccines
• Others

• Therapeutic Area
• Oncological Disorders
• Autoimmune Disorders
• Infectious Diseases
• Cardiovascular Disorders
• Other Disorders

• Scale of Operation
• Preclinical / Clinical
• Commercial

• Company Size
• Large
• Mid-sized
• Small

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

The report features inputs from eminent industry stakeholders, according to whom, a significant increase in the demand for cell and gene therapies is driving the growth of the biologics fill / finish market. The report includes detailed transcripts of discussions held with the following experts:

• Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
• Matt Delaney (Vice President Business Development & Marketing, Cytovance Biologics)
• Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
• Ales Sima (Business Development Manager, Oncomed Manufacturing)
• Amit Chandra (Technology Watch Manager, Yposkesi)
• Jos Vergeest (International Business Developer, HALIX)

The research also includes detailed profiles of key players (listed below) engaged in offering biologics fill / finish services; each profile features a brief overview of the company, its financial information (if available), details on biologics fill / finish services, location of facilities recent developments and an informed future outlook.

• AbbVie Contract Manufacturing
• Asymchem
• BioReliance
• Boehringer Ingelheim BioXcellence
• Catalent Biologics
• Charles River Laboratories
• Fareva
• Fresenius Kabi
• Glaxo SmithKline
• Hetero Drugs
• Intas Pharmaceuticals
• Lonza
• Patheon
• Pierre Fabre
• Recipharm
• Samsun Biologics
• Syngene
• Takara Bio
• Wacker Biotech
• WuXi AppTec
• WuXi Biologics

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/biologics-fill-finish-services-market/256.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com